Standardization of Models and Methods Used to Assess Nanoparticles in Cardiovascular Applications
β Scribed by Kathleen T. Fitzgerald; Carolyn A. Holladay; Cathal McCarthy; Karen A. Power; Abhay Pandit; William M. Gallagher
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 485 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1613-6810
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Nanotechnology has the potential to revolutionize the management and treatment of cardiovascular disease. Controlled drug delivery and nanoparticleβbased molecular imaging agents have advanced cardiovascular disease therapy and diagnosis. However, the delivery vehicles (dendrimers, nanocrystals, nanotubes, nanoparticles, nanoshells, etc.), as well as the model systems that are used to mimic human cardiac disease, should be questioned in relation to their suitability. This review focuses on the variations of the biological assays and preclinical models that are currently being used to study the biocompatibility and suitability of nanomaterials in cardiovascular applications. There is a need to standardize appropriate models and methods that will promote the development of novel nanomaterialβbased cardiovascular therapies.
π SIMILAR VOLUMES
## Background There have been few reports of pharmacokinetic models that have been linked to models of the cardiovascular system. Such models could predict the cardiovascular effects of a drug under a variety of circumstances. Limiting factors may be the lack of a suitably simple cardiovascular mod
Estimating log P (logarithm of "1-octanol to water" partition coefficients) as a memure of lipophilicity for organic compounds is of considerable importance in drug discovery. Several methods have been developed for this purpose, each with its own drawbacks and advantages. In this article, a systema
## Abstract The analyses of data provided for the cardiovascular disease section of Genetic Analysis Workshop 8 are briefly summarized. Methods using twin, segregation, and linkage analyses are used to determine, characterize, and localize genetic components involved in the etiology of cardiovascul